Italia markets close in 6 hours 3 minutes
FTSE MIB
34.196,45 -99,86 (-0,29%) Dow Jones
38.386,09 +146,43 (+0,38%) Nasdaq
15.983,08 +55,18 (+0,35%) Nikkei 225
38.405,66 +470,90 (+1,24%) Petrolio
82,79 +0,16 (+0,19%) Bitcoin EUR
58.726,11 -631,68 (-1,06%)
Neurocrine Biosciences, Inc. (NBIX)
NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
Alla chiusura: 04:00PM EDT
Dopo ore:
| Chiusura precedente | 135,99 |
| Aperto | 136,05 |
| Denaro | 138,75 x 200 |
| Lettera | 139,02 x 200 |
| Min-Max giorno | 136,05 - 139,37 |
| Intervallo di 52 settimane | 89,04 - 148,37 |
| Volume | |
| Media Volume | 890.980 |
| Capitalizzazione | 13,97B |
| Beta (5 anni mensile) | 0,28 |
| Rapporto PE (ttm) | 56,23 |
| EPS (ttm) | 2,47 |
| Prossima data utili | 01 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | 29 dic 1995 |
| Stima target 1A | 153,29 |
GlobeNewswireSosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat
© 2024 Yahoo. Tutti i diritti riservati.